Saturday, August 12, 2017

FDA approves two drugs for certain types of AML

A scanning electron 
microscope image 
from normal circulating 
human blood. – Wikipedia

CANCER DIGEST – Aug. 12, 2017 – The FDA approved two new drugs for treatment of specific types of acute myeloid leukemia (AML), a rapidly progressing cancer that forms in the bone marrow.

Vyxeos was approved for two types of AML, newly diagnosed therapy-related AML called t-AML, and myelodysplasia-related changes changes called ALM-MRC. 

Monday, August 7, 2017

Targeted radiotherapy reduces side effects of breast cancer surgery


CANCER DIGEST – Aug. 7, 2017 – Targeting the tumor site with radiotherapy after surgery to remove breast cancer resulted in fewer long-term side effects five years later, according to a new British study.

The researchers at 30 radiotherapy centers across the UK, led by The Institute of Cancer Research, London, and the Cancer Research UK Cambridge Centre, studied more than 2,000 women aged 50 or over who had early stage breast cancer that was at a low risk of coming back. The results of the study were published in the Aug. 2, 2017 The Lancet.

Saturday, July 29, 2017

Agent makes tumors glow for surgeons

Image courtesy Penn Medicine
CANCER DIGEST – July 29, 2017 – Using a combination of imaging technologies and an agent that makes tumors glow, surgeons identified and removed more cancerous nodules from lung cancer patients than they would have using preoperative PET scans alone, researchers report.
The study by researchers at the Abramson Cancer Center of the University of Pennsylvania combined pre-operative PET scans with a molecular imaging technique during surgery using a contrast dye that is taken up by tumors and makes them glow. The glowing tumors are then easier for surgeons to see and remove.

Saturday, July 22, 2017

Can CAR T-cells overcome glioblastmas?

CANCER DIGEST – July 21, 2017 – Glioblastoma, the aggressive and deadly form of brain cancer Senator John McCain was diagnosed with this past week, has been shown to be resistant to most current treatments.

In a study also reported this week in the journal Science Translational Medicine 
researchers at the Perelman School of Medicine at the University of Pennsylvania used T cells genetically modified to kill cancerous glial cells called glioblastoma. 

Saturday, July 15, 2017

FDA panel recommends approval for gene-altering therapy


CANCER DIGEST – July 15, 2017 – A FDA advisory panel unanimously recommended approval of a gene-altering therapy for a deadly form of childhood leukemia. If given final approval, it would be the first such drug in a new class of therapy called CAR T-cell therapy.